Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study
- 346 Downloads
To evaluate the metabolic effects of first-line somatostatin analogues or surgery in acromegaly. Retrospective, comparative, 12-month follow-up. Two hundred and thirty one patients (123 men, age 47.32 ± 14.63 years) with active acromegaly, first line treatments were somatostatin analogues in 151 (65.4%) and surgery in 80 (34.6%). Metabolic syndrome (MS) parameters, glucose, insulin and GH during oral glucose tolerance test, stimulated insulin sensitivity by insulin sensitivity index (ISI Matsuda), early and total insulin-secretion rate by insulinogenic index and AUCINS, visceral adiposity function, expressed by visceral adipose index (VAI). Somatostatin analogues treatment improved all MS parameters and significantly reduced fasting glucose (P < 0.001), HbA1c (P = 0.014) and the prevalence of DM (P = 0.003) when disease control was achieved. Both somatostatin analogues and surgery improved ISI Matsuda (P < 0.001) and reduced AUCINS (P < 0.001) and VAI (P < 0.001 and P = 0.003, respectively). Only in controlled somatostatin analogues-treated patients a significant reduction in insulinogenic index (P = 0.010) was observed. ISI Matsuda showed a significant independent correlation with IGF-1 levels (β = −0.258; P = 0.001) and VAI score (β = −0.430; P < 0.001). VAI was independently correlated with IGF-1 (β = 0.183; P = 0.004). Both somatostatin analogues and surgery can safely be used as first-line therapy in acromegaly, without any untoward effects on glucose tolerance. The control of acromegaly is the main determinant of beneficial effects on general features of insulin sensitivity. VAI could represent an additional link between disease control and insulin sensitivity.
KeywordsGH IGF-I Acromegaly Pituitary Glucose Insulin
This study has been supported in part by grants of Italian Minister of Research (MIUR)”, no. 2003068735.
Conflict of interest
Annamaria Colao is recipient of unrestricted support from Ipsen, Novartis and Pfizer for studies in neuroendocrinology. The other authors have nothing to disclose.
The authors declare that the experiments comply with the current Italian laws.
- 4.Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S (2003) Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242–1247PubMedGoogle Scholar
- 6.Colao A, Baldelli R, Marzullo P, Ferretti F, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193–199PubMedCrossRefGoogle Scholar
- 7.Sherlock M, Woods C, Sheppard MC (2011) Medical therapy in acromegaly. Nat Rev Endocrinol 7(5):291–300Google Scholar
- 8.Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, von Werder K, Wass J, Giustina A, for the Acromegaly Treatment Consensus Workshop Participants’ (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054–4058PubMedCrossRefGoogle Scholar
- 10.Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J, SMS995B2401 Study Group (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66(6):859–868CrossRefGoogle Scholar
- 16.Karaca Z, Tanriverdi F, Elbuken G, Cakir I, Donmez H, Selcuklu A, Durak A, Dokmetas H, Colak R, Unluhizarci K, Kelestimur F (2011) Comparison of primary octreotide-LAR and surgical treatment in newly diagnosed patients with acromegaly. Clin Endocrinol (Oxf). doi: 10.1111/j.1365-2265.2011.04106.x [Epub ahead of print]
- 17.Tzanela M, Vassiliadi DA, Gavalas N, Szabo A, Margelou E, Valatsou A, Vassilopoulos C (2011) Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin Endocrinol (Oxf). doi: 10.1111/j.1365-2265.2011.03996.x [Epub ahead of print]
- 18.Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A, Arosio M (2006) Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91:121–128PubMedCrossRefGoogle Scholar
- 20.Cambuli VM, Galdiero M, Mastinu M, Pigliaru F, Auriemma RS, Ciresi A, Pivonello R, Amato M, Giordano C, Mariotti S, Colao A, Baroni MG (2011) Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for GH excess and for hyperglycaemia. J Endocrinol Invest [Epub ahead of print]Google Scholar
- 23.Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso LF, Lombardi G, Pivonello R (2009) Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-years observational, open, prospective study. J Clin Endocrinol Metab 94:528–537PubMedCrossRefGoogle Scholar
- 25.Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E, The participants of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous medical Education) Study Group (2006) J Endocrinol Invest 29:1017–1020Google Scholar
- 28.American Association of Clinical Endocrinologists (2000) The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management—2000 update. Endocr Pract 6(1):43–84Google Scholar
- 33.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: executive summary of the third report of the National Cholesterol Education Program (NCEP). J Am Med Assoc 285:2486–2497Google Scholar
- 42.Bengtsson BA, Brummer RJ, Bosaeus I (1990) Growth hormone and body composition. Horm Res 33(Suppl 4):19–24Google Scholar
- 44.Richelsen B (1997) Action of growth hormone in adipose tissue. Horm Res 48(Suppl 5):105–110Google Scholar
- 46.Freda PU, Shen W, Heymsfield SB, Reyes-Vidal CM, Geer EB, Bruce JN, Gallagher D (2008) Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab 93:2334–2343PubMedCrossRefGoogle Scholar